MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds received from
issuance of common stock,...
$7,999,988
Proceeds received from
exercise of prefunded...
$6
Net cash provided by
(used in) financing...
$7,241,112
Canceled cashflow
$758,882
Net change in cash
$543,102
Canceled cashflow
$6,698,010
Payments of transactions
cost
$758,882
Stock-based compensation
$146,714
Change in fair value of
derivative liabilities
$108,627
Prepaid expenses and
other receivables
-$62,879
Net cash used in
operating activities
-$6,698,010
Canceled cashflow
$318,220
Accrued liability -
related party
-$4,125,000
Net loss
-$2,292,064
Accounts payable -
related party
-$539,834
Other payables and
accrued liabilities
-$59,332
Back
Back
Cash Flow
source: myfinsight.com
Estrella Immunopharma, Inc. (ESLA)
Estrella Immunopharma, Inc. (ESLA)